Anna Miquel-Cases Valesca P Retèl Bianca Lederer Gunter von Minckwitz Lotte M G Steuten Wim H van Harten
10.1371/journal.pone.0154386
PLoS One
2016 Apr 28;11(4):e0154386.
CC BY
https://pubmed.ncbi.nlm.nih.gov/27124410/
Breast Neoplasms / economics Cost-Benefit Analysis Drug Monitoring / methods Models, Statistical Neoadjuvant Therapy / economics
Breast Neoplasms / economics Cost-Benefit Analysis Drug Monitoring / methods Models, Statistical Neoadjuvant Therapy / economics Randomized Controlled Trial Research Support, Non-U.S. Gov't Breast Neoplasms / diagnosis Breast Neoplasms / drug therapy Breast Neoplasms / mortality Cyclophosphamide / therapeutic use Decision Trees Docetaxel Doxorubicin / therapeutic use Early Diagnosis Female Humans Proportional Hazards Models Quality-Adjusted Life Years Taxoids / therapeutic use Taxoids Docetaxel Doxorubicin Cyclophosphamide
PMC4849576
27124410
Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
2016